Johnson & Johnson raises dividend for 56th consecutive year (+7.1%)
Dividend Aristocrat Johnson & Johnson (JNJ) will increase its quarterly dividend by 7.1 percent to $0.90 per share in the second quarter of 2018. This marks the 56th year of higher dividends by the health care giant.
Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 7.1% increase in the quarterly dividend rate, from $0.84 per share to $0.90 per share. The increase was announced this morning at the Annual Meeting of Shareholders in New Brunswick, N.J.
The next quarterly dividend is payable on June 12, 2018 to shareholders of record as of the close of business on May 29, 2018. The ex-dividend date is May 25, 2018. The new dividend yield for JNJ is 2.8%.
Last year J&J raised its dividend for the 55th consecutive year.
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 7.1% increase in the quarterly dividend rate, from $0.84 per share to $0.90 per share. The increase was announced this morning at the Annual Meeting of Shareholders in New Brunswick, N.J.
The next quarterly dividend is payable on June 12, 2018 to shareholders of record as of the close of business on May 29, 2018. The ex-dividend date is May 25, 2018. The new dividend yield for JNJ is 2.8%.
"In recognition of our 2017 results, strong financial position and confidence in the future of Johnson & Johnson, the Board has voted to increase the quarterly dividend for the 56th consecutive year," said Alex Gorsky, Chairman and Chief Executive Officer of the company.
Last year J&J raised its dividend for the 55th consecutive year.
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.